Estimation of the incidence of febrile neutropenia in women receiving docetaxel plus cyclophosphamide as adjuvant therapy for early-stage breast cancer: a large community-based retrospective study

Abstract

Results: The overall incidence of G-CSF use was 91%, with 73% of patients receiving primary G-CSF prophylaxis and 9% receiving secondary G-CSF prophylaxis. The incidence of FN was 5% of patients (31), with 71% of those 31 patients (22) experiencing FN in the first cycle of treatment. Grade 3 or 4 neutropenia occurred in 43% of patients, and neutropenia-related hospitalizations occurred in 4%. Overall, 88% of patients completed 4 cycles of TC therapy, and 89% had a relative dose intensity 85%. Conclusions: This is the largest community-based retrospective study to evaluate FN incidence in patients with ESBC who are treated with TC. The results suggest that G-CSF prophylaxis may be required to safely administer TC. When TC is administered with G-CSF prophylaxis, the rates of FN and clinically significant myelosuppression are similar to the rates for other taxanecontaining regimens used for ESBC.